Our findings demonstrate that although the transcript levels of ADA are not decreased in Severe IPF and Stage 4 COPD patients, the enzymatic activity of ADA is significantly reduced in these patients. This evidence concerns the gene ADA and chronic obstructive pulmonary disease.